Published in Eur J Pharmacol on August 15, 1986
B1 bradykinin receptors and sensory neurones. Br J Pharmacol (1996) 0.99
Bradykinin and asthma. Thorax (1992) 0.92
The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist. Proc Natl Acad Sci U S A (1994) 0.91
Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta. Br J Pharmacol (1992) 0.90
Structure-activity studies on bradykinin and related peptides: agonists. Br J Pharmacol (1990) 0.87
A competitive kinin receptor antagonist, [DArg0, Hyp3, DPhe7]-bradykinin, does not affect the response to nasal provocation with bradykinin. Br J Clin Pharmacol (1991) 0.84
Development of hyperthermia following intracerebroventricular administration of endotoxin in the rat: effect of kinin B1 and B2 receptor antagonists. Br J Pharmacol (1996) 0.76
Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 8.11
Patient participation in decision-making. Soc Sci Med (1998) 8.05
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract (1995) 5.03
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med (1999) 3.98
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet (1999) 3.61
Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother (2003) 3.24
Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med (2005) 3.21
Identification of human mononuclear leucocyte populations by esterase staining. Clin Exp Immunol (1977) 3.12
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Management of traumatic intracranial haematoma. Br Med J (Clin Res Ed) (1982) 2.79
Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc (2001) 2.67
Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol (1999) 2.56
Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci U S A (1986) 2.48
Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (1987) 2.31
Pharmacology of angiotensin. Pharmacol Rev (1974) 2.25
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein. J Virol (1995) 2.23
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1996) 2.12
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
Spatial and temporal operation of the Scotia Sea ecosystem: a review of large-scale links in a krill centred food web. Philos Trans R Soc Lond B Biol Sci (2007) 1.95
Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol (1993) 1.92
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci (1988) 1.83
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs (2001) 1.74
Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur J Pharmacol (1985) 1.64
In vitro replication of adeno-associated virus DNA. Proc Natl Acad Sci U S A (1992) 1.60
Selective agonists for substance P and neurokinin receptors. Neuropeptides (1987) 1.51
Pharmacological receptors for substance P and neurokinins. Life Sci (1987) 1.50
Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol (1992) 1.50
Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol (1988) 1.49
The use of the laryngeal mask airway in primary anaesthesia. Anaesthesia (1990) 1.48
Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol (1983) 1.47
Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol (2008) 1.46
De novo formation of vascular receptors for bradykinin. Can J Physiol Pharmacol (1978) 1.45
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol (2000) 1.43
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 1.41
New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci (1990) 1.40
Oral oseltamivir in human experimental influenza B infection. Antivir Ther (2000) 1.39
Accuracy of a computer-based anaesthetic audit system. Anaesthesia (1993) 1.38
Retracted High rate of human papillomavirus type 16 infection in cytologically normal cervices. Lancet (1989) 1.38
The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol (2000) 1.38
An analysis of the negative inotropic action of somatostatin. Br J Pharmacol (1979) 1.37
Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 1.37
Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem (1997) 1.36
Growth regulatory properties of endothelins. Peptides (1993) 1.35
Generation and characterization of a defined mutant of Streptococcus suis lacking suilysin. Infect Immun (2001) 1.34
Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension (2001) 1.33
The actions of kinin antagonists on B1 and B2 receptor systems. Eur J Pharmacol (1986) 1.31
Comparative analysis of the exopolysaccharide biosynthesis gene clusters from four strains of Lactobacillus rhamnosus. Microbiology (2005) 1.29
Muscle fibre type changes in hypothyroid myopathy. J Clin Pathol (1975) 1.26
Competitive antagonists discriminate between NK2 tachykinin receptor subtypes. Br J Pharmacol (1990) 1.26
Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest (1993) 1.25
Care management and mental health. BMJ (1993) 1.25
The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol (1989) 1.24
In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. J Pharmacol Exp Ther (1991) 1.24
Receptors for substance P. I. The pharmacological preparations. Eur J Pharmacol (1984) 1.24
Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function. Neuropeptides (1991) 1.24
Different receptors are involved in the endothelium-mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery in response to substance P and related neurokinins. Eur J Pharmacol (1986) 1.24
Rat vas deferens: a specific bioassay for endogenous opioid peptides. Br J Pharmacol (1978) 1.24
Relative potencies of neurokinins in guinea pig trachea and human bronchus. Eur J Pharmacol (1987) 1.22
Kinin receptor subtypes. J Cardiovasc Pharmacol (1990) 1.21
Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol (1991) 1.19
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Effect of rapid and conventional cooling methods on the quality of cooked ham joints. Meat Sci (2000) 1.18
The C-terminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors. Eur J Pharmacol (1989) 1.17
Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun (1992) 1.17